GlaxoSmithKline (GSK) will donate $ 1 million in vaccines against cervical cancer to reduce the deaths from cancer in women.

The Pink Ribbon Red Ribbon Association is an initiative led by George w. Bush Institute, President ’ s Emergency Plan for AIDS Relief (PEPFAR), Susan g. Komen for Cure ® and the United Nations programme for HIV/AIDS (UNAIDS). The programme will seek to expand prevention and programmes of diagnosis and treatment of cervix and cancers of the breast cancer in developing countries.

Duncan Learmouth, Senior Vice President, Developing Countries and Market Access of GlaxoSmithKline, said: share with the Pink Ribbon Red Ribbon Association commitment to identify and develop innovative models that are effectively to patients and health professionals on the prevention of cancer in developing countries. It is a sad reality that every year is diagnosed thousands of women cancer of cervix, cancer potentially preventable. We will continue to support programmes that seek to increase the accessibility of women in developing countries, which are the most vulnerable to this dangerous disease ”.

The Pink Ribbon Red Ribbon Association will strengthen the platform and the resources of the President ’ s Emergency Plan for AIDS Relief (PEPFAR) of the United States, created by President Bush and that is the cornerstone of the Global Health Initiative (GHI) from the President Obama, to increase the prevention of cervical cancer vaccination and screeningas well as other treatment services.

Eric Bing, Senior Fellow and Director of Global Health at the George w. Bush Institute stated: appreciate your donation to the Pink Ribbon Red Ribbon initiative to GlaxoSmithKline. Our goal is to reduce the number of deaths by cervical cancer approximately 25 per cent among women vaccinated, screened and treated through this initiative; significantly increase access to the prevention of cervical cancer, its diagnosis, treatment and awareness about breast cancer programs; and the creation of innovative models that can adapt to a global scale. The generosity of our partners and their commitment to saving lives is a key part to ensure that we can achieve our objectives. ”

globally, cervical cancer is the third most common cancer and the third cause of death from cancer in women, with a significant proportion in developing (1). It is estimated that by 2020, the women in these countries will suffer 90 per cent of deaths for this type of cancer worldwide (2). It is estimated that only 5 per cent of these women them has been a preventive screening (PAP) of cervical cancer in the past five years (3). Vaccination and the PAP are the key elements for the prevention and control of cervical cancer.

GSK support the Pink Ribbon Red Ribbon Association strengthens the more than two decades of collaboration with leading international organizations in helping to ensure global access to vaccines.

– Every two minutes a woman dies of cancer of the cervix in the world. (4)

-along with a regular screening (PAP), vaccination can help protect girls and women against the virus of human papillomavirus (HPV) types that cause cancer of cervix more frequently. (5)

-cervical cancer also implies physical and emotional damage in women. (6)

-today, Cervarix ® has been approved in more than 110 countries around the world. Cervarix ® has also received the status of suitability of the World Health Organization that allows international organizations to purchase the vaccine in collaboration with developing countries at prices more affordable.

– as with all medicines, there are adverse effects associated with vaccination against HPV. The most common adverse effects associated with the use of Cervarix ® include reactions in the place where the booster as pain, redness, swelling and fatigue. Generally, these effects are transient and not last more than three days. More information on the tab technique of Cervarix ®, section 4.8.7

– in 2010, the 1.4 billion doses of vaccine distributed by GlaxoSmithKline, more than 1 billion was allocated to countries in development

About GlaxoSmithKline

GlaxoSmithKline (GSK), one of the world leading companies in research-based pharmaceutical and health care, with the aim improving the quality of life of people, making it possible that people have more vitality, feel better and live longer.

–
References

1. International Agency for Research on Cancer. Cervical Cancer Incidence and Mortality Worldwide in 2008: Summary. Available here! ([accessed: August 22, 2011])

2. International Agency for Research on Cancer. Cervical Cancer Incidence and Mortality Worldwide in 2008: Summary. Available here. (accessed: August 22, 2011)

3. Preventing Cervical Cancer Worldwide. Population Reference Bureau and the Alliance for Cervical Cancer Prevention. available here. (Accessed September 8, 2011)

4. International Agency for Research on Cancer. Cervical Cancer Incidence and Mortality Worldwide in 2008: Summary. Available here. (Accessed: August 22, 2011)

5 Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, Franco e. proclaiming clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J National Cancer Inst 2004b; 96: 604-615. 13

6. Based-Engquist K, Paskett ED et to the. Cervical cancer. Behavioral Factors Related to Screening, Diagnosis, and Survivors ’ Quality of Life. Cancer. 2003; 98: 2009-2014.

7. Cervarix Summary of Product Characteristics, GlaxoSmithKline, March 2011.